<DOC>
	<DOCNO>NCT00654095</DOCNO>
	<brief_summary>Evaluate safety long-term ( 1 year ) coadministration ezetimibe atorvastatin participant hypercholesterolemia reach low density lipoprotein ( LDL ) -cholesterol target 3-hydroxy-3-methylglutaryl-coenzyme A ( HMG-CoA ) reductase inhibitor .</brief_summary>
	<brief_title>Coadministration Ezetimibe Atorvastatin Patients With Primary Hypercholesterolemia ( P05456 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Participants hypercholesterolemia satisfy follow criterion : Participants use follow 3hydroxy3methylglutarylcoenzyme A ( HMGCoA ) reductase inhibitor ( hereinafter refer `` statin '' ) 4 week longer start observation period whose low density lipoprotein ( LDL ) cholesterol level treatment reach lipid management target Age : 20 year age old ( time obtain informed consent ) Sex : male female Inpatient/outpatient : Outpatient Participants follow applicable : Participants whose fasted triglyceride level measure start observation period treatment period exceed 500 mg/dL Participants homozygous familial hypercholesterolemia Participants creatine phosphokinase ( CPK ) &gt; 2x upper limit normal ( ULN ) measure start observation period treatment period . Participants serious hepatic disorder , participant alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2x ULN measure start observation period treatment period . Participants history hypersensitivity ingredient ezetimibe tablet atorvastatin tablet Pregnant , nurse woman , woman may pregnant , participant wish pregnant study . Participants discontinue use serum lipid lower agent less 4 week start treatment period ( 8 week case probucol ) . ( However , participant take serum lipid lowering agent test conduct start observation period , period discontinuation 27 day , 55 day case probucol , allow . ) Participants use cyclosporine start observation period Participants history ezetimibe use Participants hyperlipidemia associate following disease : Hypothyroidism Obstructive gall bladder biliary disease Chronic renal failure Pancreatitis Participants hyperlipidemia associate concomitant use drug adverse effect serum lipid , etc Participants receive investigational drug within 4 week start observation period Other participant deem appropriate study entry investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>